Quantitative muscle strength will be measured using the CINRG Quantitative Measurement System (CQMS)

Primary strength endpoints will be quantitative myometry (QMT) scores of the upper and lower extremities, consisting of paired flexor/extensor groups.

Secondary strength endpoints will include individual QMT scores of elbow and knee flexors and extensors and hand grip, manual muscle testing scores, which will be measured using the Medical Research Council's (MRC) muscle strength scoring method.

To describe, inclusive of the perspectives and voices of all of the major participants, the shared experiences of parents, clinician researchers, and industry professionals who were involved in phase II clinical trials for Duchenne Muscular Dyst...

21

All

18 Years to 99 Years (Adult, Older Adult)

NCT01182324

99991017110-HG-N171

July 30, 2010

June 24, 2013

August 16, 2010

April 5, 2018

National Human Genome Research Institute (NHGRI), 9000 Rockville PikeBethesda, Maryland, United States

In this phase 1 clinical trial, safety will be measured via gentamicin trough levels, audiology, and renal function tests. These lab tests will remain in the normal range while infusing gentamicin twice a week for 6 month.

Determine if gentamicin given over six months improves muscle strength.

Determine if gentamicin given over six months increases dystrophin binding at the muscle membrane.

12

Male

5 Years to 20 Years (Child, Adult)

NCT00451074

NS0431867R01NS043186

March 2007

July 2009

July 2009

March 23, 2007

March 23, 2012

Neuromuscular Research Institute - Scottsdale Healthcare Hopsital at SheaScottsdale, Arizona, United States

University of KansasKansas City, Kansas, United States

The Research Institute at Nationwide Children's HospitalColumbus, Ohio, United States